Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase 3 1

Status

Recruiting 5

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Prostatic Neoplasms 30Lung Neoplasms 30Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Multiple Myeloma 22Breast Neoplasms 20Lymphoma 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Myelodysplastic Syndromes 14Lymphoma, Large B-Cell, Diffuse 14Colorectal Neoplasms 14Pancreatic Neoplasms 11Neoplasm Metastasis 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Mouth Neoplasms 10Glioma 10Glioblastoma 10Burkitt Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Triple Negative Breast Neoplasms 8Sarcoma 8Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Lymphoma, Non-Hodgkin 8Laryngeal Neoplasms 8Carcinoma 8

Interventions

Tamoxifen 10Specimen Handling 5Chemotherapy, Adjuvant 5Radiotherapy 3Mastectomy, Segmental 3Anastrozole 3Simvastatin 2telapristone acetate 1ruxolitinib 1exemestane 1abemaciclib 1Vinorelbine 1Trastuzumab 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Sugars 1Starch 1Soybean Proteins 1Radiation Dose Hypofractionation 1Radiation 1Protons 1Proton Therapy 1Probiotics 1Pharmacogenomic Testing 1Omacor 1Neoadjuvant Therapy 1Naltrexone 1Mastectomy, Subcutaneous 1Lovastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Breast Carcinoma In Situ × Specimen Handling × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT05941520 2026-05-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
80 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-05-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
200 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06538389 2026-04-30

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

City of Hope Medical Center

Phase 2 Recruiting
36 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT07044310 2025-07-29

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Mayo Clinic

Phase 2 Recruiting
38 enrolled
Breast

Breast Carcinoma In Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡